CSQ Bio has established a surgical commercialization business and introduced INNESTO Rx, a bovine collagen powder scheduled for US sales in January 2027. The product uses an existing FDA-cleared device platform, but clinical differentiation, reimbursement and distribution economics remain unproven.
Glaukos iDose TR shows an additional 3.6 mmHg pressure reduction with cataract surgery. Examine the Phase 4 data and adoption implications.
Verda Healthcare partners with AstranaCare in Texas and Arizona ahead of Medicare enrollment. Discover the network and growth implications.
MolDX coverage now includes RaDaR ST for monitoring immune-checkpoint inhibitor response in late-stage solid tumors, expanding reimbursement while current ASCO guidance still treats ctDNA as complementary rather than a replacement for standard assessment.
Veloxis Pharmaceuticals will pay over $46 million over Envarsus XR conduct. See why five years of compliance oversight could matter even more.
Segal projects a 9.9% medical plan cost trend for 2027 as GLP-1 drugs, AI coding and arbitration intensify employer cost pressure.
Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?
Imbed Biosciences secured CMS HCPCS code A2040 for Microlyte PainGuard. Read what it changes for wound care adoption, billing, and reimbursement.